Avalon pharma and Bio-Thera execute exclusive commercialization agreement for BAT2406, a proposed Dupixent® Biosimilar, for MENA
2026-08-18
Partnership
Press Release
Avalon Pharma and Bio-Thera Solutions have signed an exclusive commercialization and license agreement for BAT2406, a proposed biosimilar to Dupixent®, covering Saudi Arabia and the wider MENA region.
Bio-Thera will lead development, manufacturing and supply, while Avalon Pharma will drive regulatory approval and commercialization — expanding access to advanced therapies for patients living with Type 2 inflammatory diseases.
A new milestone in our journey to build a stronger regional footprint in immunology and biosimilars.
AvalonPharma BioThera BAT2406 Biosimilars Dupixent MENA SaudiVision2030
Avalon pharma and Bio-Thera.pdf
Stay informed about the future of healthcare
Visit our newsroom today to stay up to date.
